Abstract： Objective To understand the application status of trastuzumab plus pertuzumab combined with taxanes(THP)regimen in clinical practice,and evaluate the efficacy,safety and tolerability of THP regimen.Methods 70 patients with HER-2 positive breast cancer,who received THP neoadjuvant regimen and completed sequential surgery at 11 tertiary-level A hospitals in Hebei Province,were selected as study subjects.A special patient data collection form was developed,and specialized person were responsible for collecting the clinical pathologic data of patients who met the inclusion criteria so as to assess the effectiveness,safety and tolerability of the THP regimen.The primary study endpoints were the rate of pathologic complete response(pCR),the incidence rate of adverse events grade≥3,and completion rate of the established treatment regimen.Results The pCR rate of the total population was 54.3％.Subgroup analysis showed that the pCR rate of cTNM stage Ⅰ-Ⅱ,hormone receptor-negative,HER-2 IHC3+patients was higher than that of cTNM stage Ⅲ,hormone receptor-positive,HER-2 IHC2+/FISH+patients,but the difference was not statistically significant(P>0.05).The pCR rate of 4 cycles of neoadjuvant therapy was higher than that with more than 4 cycles(P<0.05).The incidence rate of adverse events grade≥3 was 4.3％(3/70).The completion rate for established regiments was 98.6％(69/70).Conclusion THP regimen has been widely used in Hebei province.It is an effective neoadjuvant therapy for patients with HER-2 positive breast cancer,with good safety and tolerance.It may be considered as an alternative neoadjuvant therapy for patients with negative hormone receptors,low tumor burden,and poor tolerance to combination chemotherapy.